Form 4: Corcept Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


William Guyer, Chief Development Officer of Corcept Therapeutics Inc, sold 3,700 shares of common stock on August 4, 2026 for $113.12 per share.

Summary

  • Option exercise/conversion: acquired 3,700 Common Stock at $21.65 ($80,105) on August 4, 2026; holds 7,685 after (Direct).
  • Open-market sale: disposed of 3,700 Common Stock at $113.12 ($418,562) on August 4, 2026; holds 3,985 after (Direct).
  • Option exercise/conversion: disposed of 3,700 Stock Option (right to buy) on August 4, 2026; holds 126,300 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $418,562 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

William Guyer — Officer (Chief Development Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-04Option exercise/conversionCommon Stock3,700$22$80.1K7,685
2026-08-04Open-market saleCommon Stock3,700$113$418.6K3,985
2026-08-04Option exercise/conversionStock Option (right to buy)3,700——126,300

Key Dates

DateDescription
2026-08-04Option exercise/conversion (3,700 shares)
2026-08-04Open-market sale (3,700 shares)
2026-08-04Option exercise/conversion (3,700 shares)

Keywords

insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, bearish, William Guyer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.